NervGen Pharma Reports First Quarter 2021 Results
Vancouver, Canada. May 20, 2021 – NervGen Pharma Corp. (TSX-V: NGEN; OTCQX: NGENF) (“NervGen” or the “Company”), a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system injuries, today reported its financial results for the first quarter ended March 31, 2021. “We achieved several key milestones in the first […]
The Outdoor Diaries: Handcycling Into the Forest
By Codi Darnell May 25, 2021 Welcome to our blog series: The Outdoor Diaries. This series is about exploring the natural world from the perspective of people with chronic conditions and/or mobility issues. While the benefits of nature are for everybody, access to it isn’t always quite as simple. The world is full of natural […]
NervGen Pharma Announces Closing of Overnight Marketed Equity Offering
Vancouver, Canada. May 12, 2021 — NervGen Pharma Corp. (TSX-V: NGEN; OTCQX: NGENF) (“NervGen” or the “Company”), a clinical stage biotech company dedicated to developing innovative treatments for nerve damage and neurodegenerative diseases, announced that it has closed its previously announced overnight, “best efforts” marketed public offering (the “Offering”) of units (the “Units”). Pursuant to […]
Adding Diverse Voices to the MS Conversation
By Codi Darnell May 11, 2021 Inclusion, diversity, representation – these words are everywhere. We are living through a time of social change where people of all backgrounds are not only working to be seen and accepted but are being sought out to give their perspectives. From POC and those in the LGBTQ+ community to […]
NervGen Pharma Grants Stock Options
Vancouver, Canada. May 7, 2021 – NervGen Pharma Corp. (TSX-V: NGEN) (OTCQX: NGENF) (“NervGen” or the “Company”), a clinical stage biotech company dedicated to developing innovative treatments for nerve damage and neurodegenerative diseases, today announced that the Company has granted 800,000 incentive stock options to an Officer of the Company exercisable at a price of […]
NervGen Pharma Announces First Subject Dosed in Phase 1 Clinical Trial of NVG-291
Vancouver, Canada. May 6, 2021 – NervGen Pharma Corp. (TSX-V: NGEN) (OTCQX: NGENF) (“NervGen” or the “Company”), a clinical stage biotech company dedicated to developing innovative treatments for nerve damage and neurodegenerative diseases, is pleased to announce today that the first subject has been dosed with NVG-291 in the Company’s Phase 1 clinical trial in […]
NervGen Pharma Announces Pricing of Overnight Marketed Equity Offering
Vancouver, Canada. May 5, 2021 — NervGen Pharma Corp. (TSX-V: NGEN; OTCQX: NGENF) (“NervGen” or the “Company”), a biotech company dedicated to creating innovative solutions for the treatment of nerve damage and neurodegenerative diseases, announced that it has priced its previously announced overnight, “best efforts” marketed public offering (the “Offering”) of units (the “Units”). Pursuant […]
NervGen Pharma Corp. Announces Overnight Marketed Equity Offering
Vancouver, Canada. May 4, 2021 — NervGen Pharma Corp. (TSX-V: NGEN; OTCQX: NGENF) (“NervGen” the “Company”), a biotech company dedicated to creating innovative solutions for the treatment of nerve damage and neurodegenerative diseases, announced that it has launched an overnight, “best efforts” marketed public offering (the “Offering”) of units (the “Units”), each Unit being comprised […]
The Outdoor Diaries: Hiking With MS
By Codi Darnell April 27, 2021 Welcome to our blog series: The Outdoor Diaries. This series is about exploring the natural world from the perspective of people with chronic conditions and/or mobility issues. While the benefits of nature are for everybody, access to it isn’t always quite as simple. Why do we go outside? There […]
NervGen Pharma Grants Stock Options
Vancouver, Canada. April 23, 2021 – NervGen Pharma Corp. (TSX-V: NGEN) (OTCQX: NGENF) (“NervGen” or the “Company”), a biotech company dedicated to creating innovative solutions for the treatment of nerve damage and neurodegenerative diseases, today announced that the Company has granted 306,000 incentive stock options to Employees and Officers exercisable at a price of $1.65 […]